backgroundxenotrop
murin
leukemia
viru
mlv
relat
viru
xmrv
relat
mlv
describ
chronic
fatigu
syndrom
cf
certain
type
prostat
cancer
addit
preval
rate
high
report
blood
donor
rais
risk
transfusionrel
transmiss
sever
laboratori
util
microneutr
assay
surrog
marker
detect
antimlv
serolog
respons
prostat
cancer
patient
report
harbor
neutral
antibodi
respons
develop
highthroughput
microneutr
assay
research
studi
blood
donor
use
retrovir
vector
pseudotyp
xmrvspecif
envelop
infect
pseudotyp
neutral
sera
macaqu
mice
challeng
xmrv
preimmun
serum
plasma
sampl
blood
donor
renotaho
area
screen
neutral
donor
sampl
gave
moder
neutral
xmrv
control
pseudotyp
howev
test
western
blot
reveal
evid
antibodi
mlv
sampl
furthermor
evid
infecti
viru
viral
nucleic
acid
observ
conclusiona
microneutr
assay
develop
detect
xmrv
appli
highthroughput
format
larg
scale
studi
although
proport
blood
donor
demonstr
abil
block
xmrv
envelopemedi
infect
found
evid
inhibit
mediat
specif
antibodi
elicit
exposur
xmrv
mlv
like
moder
neutral
mediat
anoth
nonspecif
mechan
short
histori
xenotrop
murin
leukemia
viru
mlv
relat
viru
xmrv
one
controversi
discrep
result
initi
studi
found
xmrv
nucleic
acid
andor
protein
prostat
cancer
even
low
percentag
prostat
tissu
individu
histori
prostat
cancer
contrast
sever
studi
fail
detect
xmrv
prostat
cancer
tissu
much
controversi
like
explain
pcr
nucleic
acid
contamin
despit
xmrv
origin
isol
human
prostat
cancer
sampl
likelihood
laboratori
artifact
creat
passag
human
prostat
tissu
mice
result
infect
subsequ
recombin
least
two
endogen
mlv
cell
line
creat
tissu
harbor
xmrv
like
distribut
mani
laboratori
work
prostat
cancer
controversi
surround
associ
xmrv
chronic
fatigu
syndrom
cf
anyth
greater
report
lombardi
colleagu
twothird
cf
patient
us
harbor
xmrv
compar
control
importantli
work
base
three
separ
line
evid
direct
indirect
nucleic
acid
detect
pbmc
stimul
pbmc
plasma
ii
cultur
replicationcompet
xmrv
plasma
pbmc
cocultur
human
prostat
cell
iii
serolog
evid
use
flow
cytometri
assay
addit
associ
cf
presenc
viru
plasma
blood
cell
coupl
rel
high
preval
observ
appar
healthi
control
suggest
xmrv
may
blood
transfusiontransmit
real
threat
safeti
us
blood
suppli
howev
mani
group
fail
detect
xmrv
pbmc
sampl
cf
healthi
individu
least
two
studi
tri
fulli
replic
initi
studi
use
pcr
cultur
serolog
without
convinc
evid
xmrv
either
cf
patient
healthi
control
furthermor
recent
test
specimen
lombardi
et
al
studi
reveal
previous
report
pcrposit
specimen
contamin
xmrvcontain
plasmid
sequenc
lead
partial
retract
pcr
result
lombardi
et
al
public
addit
recent
multilaboratori
blind
studi
use
previous
report
xmrvmlvposit
subject
well
valid
neg
control
demonstr
viru
cultur
assay
use
lombardi
et
al
prone
crosscontamin
thu
leav
serolog
result
possibl
evid
presenc
xmrv
mlv
human
multilaboratori
studi
assay
use
lombardi
et
al
detect
serolog
respons
specimen
howev
reactiv
consist
within
replic
plasma
sampl
statist
associ
observ
cf
patient
compar
blood
donor
three
highli
sensit
assay
studi
fail
detect
serolog
respons
specimen
microneutr
assay
use
extens
diagnost
specif
test
mani
virus
includ
alphavirus
influenza
inde
neutral
antibodi
typic
form
part
highli
specif
respons
conform
epitop
neutral
xmrv
serum
sampl
observ
prostat
cancer
patient
suggest
microneutr
assay
xmrv
would
feasibl
use
studi
gener
microneutr
assay
studi
blood
donor
look
serolog
evid
xmrvmlv
infect
base
dual
envelop
pseudoviru
dep
assay
system
recent
develop
proven
rapid
sensit
specif
highthroughput
system
antivir
drug
discoveri
target
viral
entri
assay
system
compos
two
virus
entri
target
viru
driven
xmrv
envelop
protein
pseudotyp
onto
core
report
retroviru
infect
second
intern
control
pseudoviru
mediat
unrel
envelop
includ
reduc
number
fals
posit
use
assay
screen
donor
identifi
small
number
neutral
signatur
warrant
test
anonym
plasma
whole
blood
aliquot
prepar
use
residu
sampl
left
pilot
tube
collect
routin
blood
donat
test
sampl
select
differ
donat
unit
blood
servic
reno
facil
one
two
edta
plasma
tube
use
prepar
aliquot
depend
unit
collect
type
edta
tube
two
plasma
aliquot
prepar
remain
sampl
gentli
invert
resuspend
three
four
whole
blood
aliquot
prepar
aliquot
frozen
day
prepar
donor
sampl
code
retain
linkag
donor
zip
code
resid
age
gender
raceethn
linkag
person
donor
inform
name
address
telephon
number
remov
sampl
provid
anonym
prior
shipment
bsri
subsequ
test
institut
review
board
univers
california
san
francisco
approv
studi
protocol
human
embryon
kidney
cell
clone
human
prostat
lncap
cell
obtain
atcc
grown
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
fb
penicillin
streptomycin
uml
lncap
igfp
cell
ders
detector
exogen
retrovir
sequenc
element
kindli
provid
vineet
kewalramani
nci
frederick
lacz
encod
polytrop
mlv
term
lacz
virus
gener
first
infect
cell
replicationcompet
result
cell
line
infect
replicationdefect
lacz
amlv
pseudotyp
viru
introduc
lacz
gene
cho
cell
overexpress
murin
ecotrop
mlv
receptor
previous
describ
sera
wild
mice
experiment
mockinfect
infect
xmrv
week
use
posit
neg
control
xmrv
infect
rhesu
macaqu
sera
kindli
provid
john
hackett
abbott
xmrv
envelop
env
pcr
amplifi
cell
nucleic
acid
sequenc
ident
xmrv
env
sequenc
genbank
access
number
clone
pcagg
vector
kpni
nhei
restrict
site
plasmid
encod
g
protein
vesicular
stomat
viru
vsvg
glycoprotein
lassa
viru
lassagp
well
ecotrop
mlv
envelop
describ
previous
pseudotyp
virus
hivbas
retrovir
backbon
gener
two
plasmid
one
encod
env
encod
hiv
backbon
report
gene
lucr
e
pnlluc
encod
replicationincompet
variant
molecular
clone
nef
gene
replac
firefli
luciferas
luc
report
env
vpr
gene
inactiv
previous
describ
similarli
renr
e
pnlren
construct
swap
firefli
luciferas
gene
renilla
luciferas
pseudotyp
virus
mlvbase
retrovir
backbon
gener
three
plasmid
xmrv
env
mlvbase
firefli
luciferas
report
mrpluc
mlv
gagpol
express
plasmid
hivbas
pseudovirion
produc
essenti
previous
describ
transfect
cell
correspond
hiv
construct
pnlluc
pnlren
vector
plasmid
encod
viral
envelop
per
dish
use
calcium
phosphat
transfect
method
similarli
mlvbase
pseudovirion
produc
transfect
three
plasmid
construct
per
dish
next
day
express
induc
sodium
butyr
mm
h
wash
cell
pb
replac
medium
forti
hour
transfect
supernat
filter
pore
size
filter
frozen
requir
virion
concentr
ultracentrifug
concentr
rpm
rotor
beckman
sucros
cushion
h
pellet
resuspend
hbss
buffer
aliquot
storag
result
report
virus
classifi
accord
retrovir
backbon
report
system
viral
envelop
exampl
mlvluc
xmrv
env
hivren
lassa
gp
lacz
encod
polytrop
mlv
harvest
cell
filter
pore
size
filter
frozen
neutral
assay
perform
white
tissu
cultur
plate
nunc
donor
serum
sampl
prepar
plasma
ad
thrombin
king
pharmaceut
mgcl
cacl
solut
remov
fibrin
clot
serum
supernat
transfer
new
tube
heat
inactiv
min
volum
serial
dilut
test
sera
medium
alon
transfer
assay
well
follow
either
singl
two
report
viru
mixtur
depend
purpos
assay
incub
room
temperatur
addit
lncap
cell
cellsml
well
plate
incub
two
day
co
firefli
renilla
luciferas
report
express
determin
sequenti
describ
initi
highthroughput
microneutr
assay
sera
sampl
final
dilut
test
experi
repeat
twice
gener
neutral
dose
respons
curv
select
donor
sera
sampl
serial
dilut
start
initi
dilut
assay
perform
triplic
infect
pseudovirus
mlvluc
xmrv
env
mlvluc
vsv
g
cell
infect
mlvluc
mlve
env
mlvluc
vsv
g
cell
detect
use
brightglo
luciferas
assay
system
promega
infect
lacz
encod
polytrop
mlv
cell
detect
use
galactolight
plu
system
chemiluminesc
report
detect
appli
biosystem
addit
percent
cell
infect
lacz
encod
polytrop
mlv
measur
cell
fixat
visual
blue
color
develop
microscop
use
stain
kit
invitrogen
western
blot
wb
analysi
perform
detect
antixmrvmlv
antibodi
select
donor
sera
healthi
control
previous
describ
briefli
xmrvinfect
prostat
cell
grown
complet
humec
serumfre
medium
supplement
humec
bovin
pituitari
extract
invitrogen
tissu
cultur
supernat
clarifi
centrifug
passag
filter
xmrv
purifi
ml
supernat
use
viratrap
retroviru
maxiprep
kit
bioland
scientif
llc
follow
manufactur
protocol
volum
purifi
xmrv
denatur
sdspage
sampl
buffer
min
viral
protein
separ
gel
electrophoresi
nupag
bistri
gel
invitrogen
wb
test
previous
describ
modifi
use
horseradish
peroxidas
conjug
protein
g
instead
protein
ag
seroreact
defin
reactiv
viral
envelop
andor
gag
protein
expect
size
seen
posit
control
antisera
wb
test
accur
detect
xmrv
antibodi
three
experiment
infect
macaqu
equival
detect
use
recombin
protein
recent
describ
immunoassay
rna
extract
select
donor
whole
blood
sampl
use
qiagen
viral
rna
mini
kit
isol
rna
subject
revers
transcript
mlv
revers
transcriptas
rt
roch
result
cdna
amplifi
realtim
pcr
reaction
quantifi
roch
lightcycl
qrtpcr
perform
faststart
taq
polymeras
roch
amplif
cycl
two
primer
pair
use
integras
xmrv
probe
cutoff
ct
use
evid
presenc
xmrvmlv
sequenc
specimen
posit
control
repres
recombin
plasmid
spike
whole
blood
sampl
dilut
seri
copiesml
nest
rtpcr
perform
describ
briefli
rna
extract
ml
donor
plasma
use
qiaamp
ultrasen
viru
kit
qiagen
subject
revers
transcript
employ
superscript
iii
firststrand
synthesi
system
rtpcr
invitrogen
cultur
supernat
xmrvproduc
prostat
cancer
cell
line
use
dilut
posit
control
rna
isol
amplif
xmrv
gag
sequenc
transcrib
cdna
use
first
round
amplif
primer
hotstartit
fidelitaq
master
mix
usb
nest
pcr
perform
amplif
first
round
pcr
product
two
differ
primer
pair
gagif
gagir
monitor
assay
sensit
plasmid
dna
contain
clone
fragment
xmrv
gag
includ
pcr
run
concentr
pcr
rtpcr
gapdh
control
primer
pair
forward
revers
perform
ensur
similar
level
dna
rna
input
round
amplif
develop
nation
cancer
institut
stabl
transfect
pbabeigfppuro
lncap
cell
intron
interrupt
gfp
gene
pbabeigfppuro
express
mobil
infect
gammaretroviru
second
round
infect
test
presenc
infecti
xmrv
select
donor
plasma
derselig
cell
inocul
donor
plasma
control
plasma
spin
infect
describ
gfp
express
monitor
everi
day
total
period
week
posit
control
cultur
supernat
xmrvproduc
prostat
cancer
cell
line
contain
roughli
copiesml
use
inoculum
dilut
xmrv
pseudovirus
mlvluc
xmrv
env
gener
use
mlvbase
retrovir
backbon
pseudovirus
infect
lncap
cell
expect
previou
studi
level
infect
mediat
xmrv
envelop
somewhat
lower
compar
control
envelop
exampl
cell
infect
unconcentr
mlvluc
xmrv
env
equal
vsvg
pseudotyp
viru
stock
dilut
tenfold
rel
light
unit
respect
cell
type
mlvluc
xmrv
env
neutral
sera
mice
fig
rhesu
macaqu
fig
challeng
xmrv
wherea
clear
neutral
observ
preimmun
sera
similar
result
obtain
hivluc
xmrv
env
data
shown
moreov
ecotrop
mlv
pseudovirus
mlvluc
mlve
env
also
neutral
sera
rhesu
macaqu
challeng
xmrv
fig
howev
lacz
encod
polytrop
mlv
mlvp
hivluc
vsv
g
pseudovirus
fig
neutral
develop
reliabl
highthroughput
assay
system
screen
larg
number
sampl
xmrv
infect
gener
cellbas
xmrv
microneutr
assay
system
base
internallycontrol
dual
envelop
pseudoviru
dep
assay
recent
develop
screen
small
molecul
inhibitor
proven
rapid
safe
sensit
specif
highthroughput
system
antivir
drug
discoveri
target
viral
entri
adopt
similar
approach
xmrv
microneutr
assay
assay
perform
plate
format
aid
liquid
dispens
equip
highthroughput
applic
preliminari
experi
combin
mlvluc
xmrv
env
hivren
lassa
gp
show
clear
interfer
two
envelop
chosen
sera
screen
combin
prove
give
robust
reproduc
result
combin
mlvluc
xmrv
env
hivren
lassa
gp
three
plate
indic
interpl
coeffici
variat
mlvluc
xmrv
env
hivren
lassa
gp
respect
set
sera
sampl
indic
intraassay
cv
everi
sampl
triplic
within
interassay
cv
everi
sampl
three
plate
within
mlvluc
xmrv
env
hivren
lassa
gp
data
shown
gener
sera
show
rel
higher
level
neutral
xmrv
env
pseudovirus
lassa
gp
control
fig
similar
result
obtain
sera
dilut
individu
viru
alon
lncap
cell
data
shown
despit
higher
level
background
neutral
neutral
number
sera
notic
pronounc
exampl
fig
three
donor
sera
show
approxim
reduct
xmrv
env
lassa
gp
mediat
viral
infect
cell
use
assay
screen
total
blood
donor
sera
collect
within
unit
blood
servic
region
renolak
taho
reno
facil
chosen
due
collect
territori
includ
region
northern
nevada
california
known
cluster
cf
patient
cf
cluster
includ
renolak
taho
area
form
major
subject
origin
demonstr
presenc
xmrv
blood
sera
gave
reduct
xmrv
env
lassa
gp
mediat
viral
infect
either
dilut
serum
sampl
show
dosedepend
neutral
xmrv
pseudovirus
neutral
dilut
unlik
mous
macaqu
antisera
blood
donor
sera
demonstr
limit
neutral
mlve
pseudovirus
dilut
fig
clear
neutral
detect
vsv
pseudovirus
fig
lacz
encod
polytrop
mlv
data
shown
moder
neutral
sera
well
addit
poor
neutral
donor
clear
neutral
abil
assess
recent
develop
wb
assay
use
purifi
denatur
xmrv
antigen
xmrvinfect
prostat
cell
test
blood
donor
sera
wbneg
fig
order
confirm
whether
evid
xmrv
mlv
infect
individu
would
lead
posit
serolog
respons
perform
pcr
assay
viru
cultur
would
detect
specif
xmrv
broadli
mlv
whole
blood
sampl
select
donor
test
qrtpcr
use
primer
set
locat
either
xmrv
integras
gag
posit
signal
seen
sampl
either
primer
set
data
shown
plasma
sampl
select
donor
also
test
found
neg
nest
rtpcr
use
gener
mlv
primer
previous
shown
detect
xmrv
broader
famili
xenotrop
polytrop
mlv
fig
test
presenc
infecti
mlv
donor
plasma
indic
cell
line
ders
use
posit
control
cultur
supernat
xmrvproduc
prostat
cancer
cell
line
contain
roughli
rna
copiesml
util
inoculum
wherea
cell
inocul
supernat
show
concentrationdepend
gfp
express
day
spread
viru
day
previous
describ
gfp
express
could
observ
cell
inocul
donor
plasma
seroreact
person
even
spininfect
use
enhanc
potenti
infect
effici
data
shown
determin
whether
serolog
evid
immun
respons
gammaretrovirus
human
indic
authent
infect
nonspecif
crossreact
import
final
step
xmrv
saga
studi
gener
robust
highthroughput
microneutr
assay
screen
larg
number
subject
serolog
evid
xmrv
mlv
infect
base
dep
assay
system
recent
develop
assay
includ
intern
control
pseudoviru
use
avoid
nonspecif
inhibit
also
control
cytotox
method
provid
reproduc
highthroughput
microneutr
research
assay
larg
scale
test
evid
xmrv
mlv
infect
current
enzym
immunoassay
eia
western
blot
wb
two
common
serolog
method
util
viral
diagnosi
wb
limit
recognit
linear
epitop
prone
highbackground
rate
eia
restrict
qualiti
antigen
antibodi
detect
method
instead
directli
detect
exist
antivir
antibodi
sera
depbas
microneutr
assay
base
abil
serum
neutral
pseudoviru
infect
compar
standard
assay
eia
microneutr
assay
fewer
step
perform
autom
liquid
handl
equip
may
gener
less
standard
deviat
disadvantag
twoday
incub
period
assay
impact
clinic
use
assay
recent
studi
identifi
neutral
activ
xmrv
blood
donor
sampl
although
instanc
mani
sera
neutral
control
virus
addit
xmrv
contrast
identifi
blood
donor
abl
moder
neutral
xmrv
envmedi
infect
control
mlv
envelop
poorli
neutral
none
sampl
test
show
evid
serolog
respons
xmrv
wb
test
furthermor
seroreact
sampl
neg
xmrv
mlv
sequenc
use
pcr
viru
cultur
pcr
cultur
assay
design
detect
broad
rang
gammaretrovirus
well
xmrv
specif
thu
exclud
xmrvmlv
gammaretrovirus
sourc
nonspecif
reactiv
find
neutral
blood
donor
specif
xmrv
envelop
mlv
envelop
surpris
pairwis
comparison
amino
acid
aa
sequenc
envelop
region
xmrv
mlvp
mlve
show
aa
similar
respect
given
true
xmrv
neutral
respons
rais
anim
broadli
neutral
fig
result
strongli
argu
specif
neutral
rather
suggest
moder
neutral
observ
mediat
nonspecif
mean
could
crossreact
antibodi
rais
endogen
retrovir
element
complet
unrel
protein
nonantibodi
serum
factor
human
serum
potent
inhibit
xmrv
howev
larg
complementdriven
assay
serum
complement
inactiv
heat
influenc
test
result
rel
high
level
nonspecif
greater
seen
microneutr
assay
partli
due
lack
known
human
posit
case
use
order
accur
set
cutoff
defin
specif
neutral
result
like
also
explain
report
xmrv
neutral
result
human
sampl
addit
initi
associ
xmrv
cf
made
lombardi
et
al
logic
assay
conformationallydepend
crossreact
epitop
share
mous
gammaretroviru
xmrv
would
bind
xmrv
antibodi
would
detect
flow
cytometrybas
assay
howev
like
microneutr
assay
mammalian
cell
culturebas
express
unrel
retroviru
env
would
highli
prone
nonspecif
crossreact
confound
test
requir
clarif
wb
analysi
use
purifi
antigen
inde
lombardi
et
al
flowbas
assay
use
two
laboratori
plasma
specimen
blind
studi
high
level
nonspecif
reactiv
observ
conclus
develop
robust
highthroughput
microneutr
assay
order
conduct
studi
look
evid
infect
xmrv
mlv
although
small
proport
blood
donor
demonstr
abil
block
xmrvmediat
infect
found
evid
inhibit
mediat
specif
antibodi
elicit
exposur
xmrv
relat
mlv
like
moder
neutral
mediat
anoth
nonspecif
mechan
find
also
explain
highli
nonreproduc
nonspecif
serolog
respons
detect
assay
addit
microneutr
assay
system
easili
adapt
screen
donor
sampl
virus
care
select
match
partner
viru
envelop
provid
import
inform
neutral
antibodi
respons
infecti
diseas
profil
shown
exampl
screen
donor
serum
sampl
dilut
xmrv
neutral
viru
combin
mlvluc
xmrv
env
hivren
lassa
gp
plate
format
three
total
donor
sera
show
approxim
reduct
xmrv
env
lassa
gp
mediat
viral
infect
cell
repres
result
donor
sampl
shown
posit
control
contain
plasmid
harbor
clone
fragment
xmrv
gag
neg
water
control
first
round
pcr
amplif
use
primer
pair
second
round
pcr
amplif
use
primer
pair
gagif
gagir
gapdh
rna
dna
pcr
result
sampl
shown
bottom
two
panel
